Onglyza litigation
Claims allege that the diabetes drug Onglyza increased the risk of hospitalization for heart failure, a finding confirmed in a major cardiovascular trial.
Free case review
What the claims allege
The SAVOR-TIMI 53 trial reported a statistically significant increase in heart failure hospitalizations among patients taking saxagliptin, and the FDA later added warnings. Claims allege the risk should have been investigated and disclosed sooner.
Injuries named in the litigation
- Heart failure and hospitalization
- Cardiac death alleged in filed claims
- Pancreatitis
Who may qualify
If you took Onglyza or Kombiglyze and were hospitalized for heart failure, you may have a claim. The review is free and confidential, and we will give you an honest answer either way. You pay attorney's fees only if we recover for you.
Call (888) 391‑1315 or use the form for a free, confidential review. You pay attorney's fees only if we recover for you.